Oxford Vaccines Group - Articles and news items

Oxford Vaccine Group initiates Phase 2 study of Ebola prime-boost vaccine regimen combining MVA-BN-Filo and Ad26.ZEBOV

Industry news / 15 July 2015 / Victoria White

Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+